Koers Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE
Aandelen
PLX
US74365A3095
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
732,5 ILa | -.--% | +3,29% | +69,68% |
Omzet 2024 * | 74,06 mln. 27,44 mld. 68,81 mln. | Omzet 2025 * | 127 mln. 47,18 mld. 118 mln. | Marktkapitalisatie | 83,58 mln. 30,96 mld. 77,66 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 17 mln. 6,3 mld. 15,8 mln. | Nettowinst (verlies) 2025 * | 70 mln. 25,93 mld. 65,04 mln. | EV/omzet 2024 * | 1,13 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,66 x |
K/w-verhouding 2024 * |
5,43
x | K/w-verhouding 2025 * |
1,41
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,27% |
Recentste transcriptie over Protalix BioTherapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30-06-19 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22-07-19 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05-07-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01-12-19 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01-12-19 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01-11-14 |
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |